The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).
 
Robert William Lentz
Consulting or Advisory Role - Myeloid Therapeutics (Inst)
Research Funding - ALX Oncology (Inst); Guardant Health (Inst); Lilly (Inst); Merck (Inst)
 
Patrick Jud Blatchford
Employment - BioMimetix; Clovis Oncology; Criterium; Worldwide Clinical Trials Holdings, Inc.
Consulting or Advisory Role - BioMimetix; Clovis Oncology; Criterium; Worldwide Clinical Trials
 
Junxiao Hu
No Relationships to Disclose
 
Todd Pitts
Research Funding - ALX Oncology; AstraZeneca; Exelixis; Takeda
 
Adrie van Bokhoven
No Relationships to Disclose
 
Hannah Ruth Robinson
No Relationships to Disclose
 
Nicole Baranda Balmaceda
No Relationships to Disclose
 
Emily Baiyee Toegel
No Relationships to Disclose
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Sunnie S. Kim
Honoraria - Merck
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Lilly; I-Mab
Research Funding - Merck
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Genentech (Inst)
 
Raymond Couric Wadlow
Honoraria - AstraZeneca; Oncocyte; Pfizer; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Exact Sciences
 
Kristen Renee Spencer
Honoraria - American Cancer Society
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Caris Life Sciences; Exelixis; TriSalus Life Sciences
Research Funding - Winn CDA
Travel, Accommodations, Expenses - ASCO; Cholangiocarcinoma Foundation
 
Aaron J. Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Patrick M Boland
Consulting or Advisory Role - Bayer; Guardant Health; Merck; Pfizer; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); Compass Therapeutics (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Merck; Processa Pharmaceuticals
Other Relationship - seage
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst); QED Therapeutics; Zymeworks
Research Funding - Agenus (Inst); ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); Exelixis (Inst); Experimental Drug Development Centre (EDDC); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)